title: HSP90 as a novel molecular target in non-small-cell lung cancer.
abstract: Lung cancer remains the most lethal cancer, with over 160,000 annual deaths in the USA alone. Over the past decade, the discovery of driver mutations has changed the landscape for the treatment of non-small-cell lung cancer (NSCLC). Targeted therapies against epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) have now been approved by the Food and Drug Administration as part of the standard first-line treatment of NSCLC. Despite good initial responses, most patients develop resistance within 8-12 months and have disease progression.
authors.affiliation: Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada.
authors.forename: Khashayar
authors.initials: K
authors.lastname: Esfahani
authors.affiliation: Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada.
authors.forename: Victor
authors.initials: V
authors.lastname: Cohen
keywords: driver mutations; heat shock protein 90 (HSP90); non-small-cell lung cancer; targeted therapy